Corcept Therapeutics (CORT) director exercises 30K options and gifts shares

Rhea-AI Filing Summary

Corcept Therapeutics director David L. Mahoney reported a series of routine equity transactions. He exercised stock options covering 30,000 shares of Common Stock at $5.86 per share, converting a derivative position into directly held shares.

To cover the exercise price through a net, cashless exercise, 5,469 shares were withheld at a value of $32.15 per share, which is a tax/payment mechanism rather than an open-market sale. The remaining 24,531 shares were transferred as a bona fide gift to the David L. Mahoney and Winnifred C. Ellis 1998 Family Trust and are now reported as indirectly owned.

After these transactions, Mahoney reports 1,237,145 shares of Common Stock held indirectly through the family trust and an additional 46,147 shares held indirectly through The Black Dog Private Foundation. The filing shows no open-market purchases or sales of Corcept Therapeutics stock.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MAHONEY DAVID L

(Last) (First) (Middle)

C/O CORCEPT THERAPEUTICS INCORPORATED

101 REDWOOD SHORES PARKWAY

(Street)

REDWOOD CITY CA 94065

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CORCEPT THERAPEUTICS INC [ CORT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/13/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/13/2026		M		30,000	A	$5.86	30,000	D
Common Stock	03/13/2026		F(1)		5,469	D	$32.15	24,531	D
Common Stock	03/13/2026		G(2)		24,531	D	$0.00	0	D
Common Stock	03/13/2026		J(2)		24,531	A	$0.00	1,237,145	I	Held by David L. Mahoney and Winnifred C. Ellis 1998 Family Trust
Common Stock								46,147	I	The Black Dog Private Foundation

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$5.86	03/13/2026		M			30,000	(3)	07/21/2026	Common Stock	30,000	$0.00	0	D

Explanation of Responses:

1. These shares were withheld so the Reporting Person could satisfy the exercise price arising from a net (cashless) exercise of stock options.

2. Transfer of shares without consideration to the David L. Mahoney and Winnifred C. Ellis 1998 Family Trust.

3. Fully exercisable.

Remarks:

The power of attorney under which this form was signed is on file with the Commission.

	/s/ Joseph Douglas Lyon, as attorney-in-fact for David L Mahoney	03/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Corcept Therapeutics (CORT) director David L. Mahoney do in this Form 4?

David L. Mahoney exercised options for 30,000 Corcept Therapeutics shares and then moved the resulting stock through tax withholding and a gift to a family trust. The transactions are routine equity administration, not open-market buying or selling.

How many Corcept Therapeutics shares did Mahoney acquire through option exercise?

Mahoney exercised stock options covering 30,000 shares of Corcept Therapeutics Common Stock at an exercise price of $5.86 per share. This converted previously granted derivative awards into directly held shares before subsequent withholding and gifting steps.

Were any Corcept Therapeutics (CORT) shares sold on the open market in this filing?

No open-market sales occurred. A total of 5,469 shares were withheld at $32.15 per share to satisfy the option exercise cost, and 24,531 shares were transferred as a bona fide gift to a family trust, both non-market dispositions.

How many Corcept Therapeutics shares are now held through Mahoney’s family trust?

Following the transactions, 1,237,145 shares of Corcept Therapeutics Common Stock are reported as indirectly owned through the David L. Mahoney and Winnifred C. Ellis 1998 Family Trust. These holdings reflect shares attributed to the trust rather than directly held by Mahoney.

What is the role of tax withholding in Mahoney’s Corcept Therapeutics Form 4?

The filing shows 5,469 shares withheld so Mahoney could satisfy the option exercise price via a net, cashless exercise. This tax and payment mechanism uses shares instead of cash and does not represent an open-market sale of Corcept stock.

What other indirect Corcept Therapeutics holdings does Mahoney report?

In addition to the family trust, Mahoney reports 46,147 Corcept Therapeutics shares held indirectly through The Black Dog Private Foundation. This entry reflects an existing indirect holding position rather than a new purchase or sale reported in this Form 4.